2023-04-262024-04-302024-04-30false14829645NEUROBIOLOGICAL TREATMENTS LTD2025-01-21falseiso4217:GBPxbrli:pure148296452023-04-26148296452024-04-30148296452023-04-262024-04-30148296452023-04-25148296452023-04-25148296452023-04-252023-04-2514829645bus:SmallEntities2023-04-262024-04-3014829645bus:AuditExempt-NoAccountantsReport2023-04-262024-04-3014829645bus:FullAccounts2023-04-262024-04-3014829645bus:PrivateLimitedCompanyLtd2023-04-262024-04-3014829645core:WithinOneYear2024-04-3014829645core:AfterOneYear2024-04-3014829645core:WithinOneYear2023-04-2514829645core:AfterOneYear2023-04-2514829645core:ShareCapital2024-04-3014829645core:SharePremium2024-04-3014829645core:RevaluationReserve2024-04-3014829645core:OtherReservesSubtotal2024-04-3014829645core:RetainedEarningsAccumulatedLosses2024-04-3014829645core:ShareCapital2023-04-2514829645core:SharePremium2023-04-2514829645core:RevaluationReserve2023-04-2514829645core:OtherReservesSubtotal2023-04-2514829645core:RetainedEarningsAccumulatedLosses2023-04-2514829645core:LandBuildings2024-04-3014829645core:PlantMachinery2024-04-3014829645core:Vehicles2024-04-3014829645core:FurnitureFittings2024-04-3014829645core:OfficeEquipment2024-04-3014829645core:NetGoodwill2024-04-3014829645core:IntangibleAssetsOtherThanGoodwill2024-04-3014829645core:ListedExchangeTraded2024-04-3014829645core:UnlistedNon-exchangeTraded2024-04-3014829645core:LandBuildings2023-04-2514829645core:PlantMachinery2023-04-2514829645core:Vehicles2023-04-2514829645core:FurnitureFittings2023-04-2514829645core:OfficeEquipment2023-04-2514829645core:NetGoodwill2023-04-2514829645core:IntangibleAssetsOtherThanGoodwill2023-04-2514829645core:ListedExchangeTraded2023-04-2514829645core:UnlistedNon-exchangeTraded2023-04-2514829645core:LandBuildings2023-04-262024-04-3014829645core:PlantMachinery2023-04-262024-04-3014829645core:Vehicles2023-04-262024-04-3014829645core:FurnitureFittings2023-04-262024-04-3014829645core:OfficeEquipment2023-04-262024-04-3014829645core:NetGoodwill2023-04-262024-04-3014829645core:IntangibleAssetsOtherThanGoodwill2023-04-262024-04-3014829645core:ListedExchangeTraded2023-04-262024-04-3014829645core:UnlistedNon-exchangeTraded2023-04-262024-04-3014829645core:MoreThanFiveYears2023-04-262024-04-3014829645core:Non-currentFinancialInstruments2024-04-3014829645core:Non-currentFinancialInstruments2023-04-2514829645dpl:CostSales2023-04-262024-04-3014829645dpl:DistributionCosts2023-04-262024-04-3014829645core:LandBuildings2023-04-262024-04-3014829645core:PlantMachinery2023-04-262024-04-3014829645core:Vehicles2023-04-262024-04-3014829645core:FurnitureFittings2023-04-262024-04-3014829645core:OfficeEquipment2023-04-262024-04-3014829645dpl:AdministrativeExpenses2023-04-262024-04-3014829645core:NetGoodwill2023-04-262024-04-3014829645core:IntangibleAssetsOtherThanGoodwill2023-04-262024-04-3014829645dpl:GroupUndertakings2023-04-262024-04-3014829645dpl:ParticipatingInterests2023-04-262024-04-3014829645dpl:GroupUndertakingscore:ListedExchangeTraded2023-04-262024-04-3014829645core:ListedExchangeTraded2023-04-262024-04-3014829645dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-04-262024-04-3014829645core:UnlistedNon-exchangeTraded2023-04-262024-04-3014829645dpl:CostSales2023-04-252023-04-2514829645dpl:DistributionCosts2023-04-252023-04-2514829645core:LandBuildings2023-04-252023-04-2514829645core:PlantMachinery2023-04-252023-04-2514829645core:Vehicles2023-04-252023-04-2514829645core:FurnitureFittings2023-04-252023-04-2514829645core:OfficeEquipment2023-04-252023-04-2514829645dpl:AdministrativeExpenses2023-04-252023-04-2514829645core:NetGoodwill2023-04-252023-04-2514829645core:IntangibleAssetsOtherThanGoodwill2023-04-252023-04-2514829645dpl:GroupUndertakings2023-04-252023-04-2514829645dpl:ParticipatingInterests2023-04-252023-04-2514829645dpl:GroupUndertakingscore:ListedExchangeTraded2023-04-252023-04-2514829645core:ListedExchangeTraded2023-04-252023-04-2514829645dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-04-252023-04-2514829645core:UnlistedNon-exchangeTraded2023-04-252023-04-2514829645core:NetGoodwill2024-04-3014829645core:IntangibleAssetsOtherThanGoodwill2024-04-3014829645core:LandBuildings2024-04-3014829645core:PlantMachinery2024-04-3014829645core:Vehicles2024-04-3014829645core:FurnitureFittings2024-04-3014829645core:OfficeEquipment2024-04-3014829645core:AfterOneYear2024-04-3014829645core:WithinOneYear2024-04-3014829645core:ListedExchangeTraded2024-04-3014829645core:UnlistedNon-exchangeTraded2024-04-3014829645core:ShareCapital2024-04-3014829645core:SharePremium2024-04-3014829645core:RevaluationReserve2024-04-3014829645core:OtherReservesSubtotal2024-04-3014829645core:RetainedEarningsAccumulatedLosses2024-04-3014829645core:NetGoodwill2023-04-2514829645core:IntangibleAssetsOtherThanGoodwill2023-04-2514829645core:LandBuildings2023-04-2514829645core:PlantMachinery2023-04-2514829645core:Vehicles2023-04-2514829645core:FurnitureFittings2023-04-2514829645core:OfficeEquipment2023-04-2514829645core:AfterOneYear2023-04-2514829645core:WithinOneYear2023-04-2514829645core:ListedExchangeTraded2023-04-2514829645core:UnlistedNon-exchangeTraded2023-04-2514829645core:ShareCapital2023-04-2514829645core:SharePremium2023-04-2514829645core:RevaluationReserve2023-04-2514829645core:OtherReservesSubtotal2023-04-2514829645core:RetainedEarningsAccumulatedLosses2023-04-2514829645core:NetGoodwill2023-04-2514829645core:IntangibleAssetsOtherThanGoodwill2023-04-2514829645core:LandBuildings2023-04-2514829645core:PlantMachinery2023-04-2514829645core:Vehicles2023-04-2514829645core:FurnitureFittings2023-04-2514829645core:OfficeEquipment2023-04-2514829645core:AfterOneYear2023-04-2514829645core:WithinOneYear2023-04-2514829645core:ListedExchangeTraded2023-04-2514829645core:UnlistedNon-exchangeTraded2023-04-2514829645core:ShareCapital2023-04-2514829645core:SharePremium2023-04-2514829645core:RevaluationReserve2023-04-2514829645core:OtherReservesSubtotal2023-04-2514829645core:RetainedEarningsAccumulatedLosses2023-04-2514829645core:AfterOneYear2023-04-262024-04-3014829645core:WithinOneYear2023-04-262024-04-3014829645core:Non-currentFinancialInstrumentscore:CostValuation2023-04-262024-04-3014829645core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-04-262024-04-3014829645core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-04-262024-04-3014829645core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-04-262024-04-3014829645core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-04-262024-04-3014829645core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-04-262024-04-3014829645core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-04-262024-04-3014829645core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-04-262024-04-3014829645core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-04-262024-04-3014829645core:Non-currentFinancialInstrumentscore:CostValuation2024-04-3014829645core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-04-3014829645core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-04-3014829645core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-04-3014829645core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-04-3014829645core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-04-3014829645core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-04-3014829645core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-04-3014829645core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-04-3014829645core:Non-currentFinancialInstrumentscore:CostValuation2023-04-2514829645core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-04-2514829645core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-04-2514829645core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-04-2514829645core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-04-2514829645core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-04-2514829645core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-04-2514829645core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-04-2514829645core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-04-2514829645bus:Director12023-04-262024-04-30

NEUROBIOLOGICAL TREATMENTS LTD

Registered Number
14829645
(England and Wales)

Unaudited Financial Statements for the Period ended
30 April 2024

NEUROBIOLOGICAL TREATMENTS LTD
Company Information
for the period from 26 April 2023 to 30 April 2024

Director

MBAYA, Patrick Samuel

Registered Address

17 Woodthorpe Grange
Prestwich
Manchester
M25 0GU

Registered Number

14829645 (England and Wales)
NEUROBIOLOGICAL TREATMENTS LTD
Balance Sheet as at
30 April 2024

Notes

2024

£

£

Current assets
Debtors311,939
Cash at bank and on hand209,994
221,933
Creditors amounts falling due within one year4(94,396)
Net current assets (liabilities)127,537
Total assets less current liabilities127,537
Net assets127,537
Capital and reserves
Called up share capital100
Profit and loss account127,437
Shareholders' funds127,537
The financial statements were approved and authorised for issue by the Director on 21 January 2025, and are signed on its behalf by:
MBAYA, Patrick Samuel
Director
Registered Company No. 14829645
NEUROBIOLOGICAL TREATMENTS LTD
Notes to the Financial Statements
for the period ended 30 April 2024

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in accordance with the Companies Act 2006 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.
Revenue from sale of goods
Revenue from the sale of goods is recognised when the company has transferred to the buyer the significant risks and rewards of ownership of the goods, usually when goods are delivered and legal title has passed. Providing the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the company and the costs incurred or to be incurred in respect of the transition can be measured reliably.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
2.Average number of employees

2024
Average number of employees during the year0
3.Debtors: amounts due within one year

2024

£
Other debtors11,939
Total11,939
4.Creditors: amounts due within one year

2024

£
Taxation and social security91,903
Other creditors993
Accrued liabilities and deferred income1,500
Total94,396